Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NALBUPHINE HYDROCHLORIDE vs ENOXAPARIN SODIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mixed agonist-antagonist at mu-opioid receptor; full agonist at kappa-opioid receptor; weak antagonist at mu-opioid receptor.
Enoxaparin binds to antithrombin III (ATIII) via its pentasaccharide sequence, enhancing ATIII-mediated inhibition of factor Xa and, to a lesser extent, factor IIa (thrombin). It preferentially inhibits factor Xa over thrombin (anti-Xa:anti-IIa ratio ~3.6:1).
Moderate to severe pain,Supplement to balanced anesthesia,Preoperative and postoperative analgesia,Obstetrical analgesia during labor and delivery
Prophylaxis of deep vein thrombosis (DVT) in abdominal or hip/knee replacement surgery,Prophylaxis of DVT in medical patients with acute illness and restricted mobility,Inpatient treatment of acute DVT with or without pulmonary embolism (PE) when administered with warfarin,Outpatient treatment of acute DVT without PE when administered with warfarin,Unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI) when administered with aspirin,Acute ST-segment elevation myocardial infarction (STEMI) managed medically or with percutaneous coronary intervention (PCI)
10-20 mg IM/IV/SC every 3-6 hours as needed; maximum single dose 20 mg, maximum daily dose 160 mg.
1 mg/kg subcutaneous every 12 hours or 1.5 mg/kg subcutaneous once daily
Terminal elimination half-life is approximately 5 hours (range 3-6 hours) in adults; prolonged in hepatic impairment.
4.5-7 hours after single subcutaneous dose; prolonged to 8-12 hours in renal impairment (Cr Cl <30 m L/min). Clinical context: maintains anti-Xa activity for 12 hours with once-daily dosing.
Hepatic via glucuronidation; primarily metabolized by UGT2B7; minor CYP450 involvement.
Enoxaparin is partially metabolized in the liver via desulfation and depolymerization by heparanase and other enzymes. It has a complex pharmacokinetic profile with dose-dependent clearance; renal excretion accounts for elimination of active fragments and the unchanged drug.
Primarily hepatic metabolism (CYP3A4 and glucuronidation); <5% excreted unchanged in urine; ~70% excreted as metabolites in urine, ~30% in feces.
Renal (40-60% as unchanged drug via glomerular filtration and saturable tubular reabsorption). Biliary/fecal: negligible (<10%).
Approximately 50% bound to plasma proteins, primarily albumin.
80% bound to antithrombin III (low affinity to other plasma proteins).
Approximately 2.6 L/kg (range 1.6-3.8 L/kg); indicates extensive tissue distribution.
0.04-0.06 L/kg (plasma volume distribution; low Vd indicates limited extravascular distribution).
Intramuscular and subcutaneous: approximately 80%; oral: low (extensive first-pass metabolism, <20% oral bioavailability).
Subcutaneous: 90-92% (complete absorption).
Cr Cl 30-50 m L/min: administer 75% of normal dose; Cr Cl 10-29 m L/min: administer 50% of normal dose; Cr Cl <10 m L/min: avoid use or use with extreme caution.
Cr Cl < 30 m L/min: reduce dose to 1 mg/kg subcutaneous once daily
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 25%; Child-Pugh Class C: reduce dose by 50% or avoid.
No specific Child-Pugh based adjustment; use with caution in severe hepatic impairment due to increased bleeding risk
0.1-0.2 mg/kg IV/IM/SC every 3-6 hours as needed; maximum single dose 20 mg.
Neonates and infants: 1.5 mg/kg subcutaneous every 12 hours; Children < 2 months: 1.5 mg/kg every 12 hours; Children ≥ 2 months: 1 mg/kg every 12 hours
Initiate at 50% of adult dose (5-10 mg) and titrate cautiously due to increased sensitivity and risk of respiratory depression.
Increased risk of bleeding; consider lower doses (e.g., 0.5 mg/kg every 12 hours or 1 mg/kg once daily) and monitor renal function
Risk of respiratory depression, abuse, misuse, and addiction; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Enoxaparin carries a black box warning for the risk of spinal or epidural hematomas in patients receiving neuraxial anesthesia or spinal puncture, which can result in long-term or permanent paralysis. Patients should be monitored for signs of neurological impairment, and concomitant use of drugs affecting hemostasis (e.g., NSAIDs, antiplatelet agents, other anticoagulants) increases the risk.
Respiratory depression; abuse potential; neonatal opioid withdrawal syndrome; adrenal insufficiency; severe hypotension; head injury and increased intracranial pressure; severe hepatic or renal impairment.
Spinal/epidural hematoma risk with neuraxial anesthesia,Increased bleeding risk, especially in patients with renal impairment, thrombocytopenia, or age >65,Heparin-induced thrombocytopenia (HIT) risk; monitor platelet counts regularly,Use with caution in patients with severe renal impairment (Cr Cl <30 m L/min), as enoxaparin accumulates and increases bleeding risk; dose adjustment required,Not recommended in patients with mechanical heart valves, especially pregnant women, due to risk of valve thrombosis,Do not mix with other injections or infusions
Hypersensitivity to nalbuphine or any component; significant respiratory depression; acute or severe bronchial asthma; paralytic ileus; suspected or known gastrointestinal obstruction; use of MAOIs within 14 days.
Active major bleeding or bleeding disorders (e.g., hemophilia, thrombocytopenic purpura),History of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis (HITT),Hypersensitivity to enoxaparin, heparin, or pork products,Not recommended for use in patients with mechanical heart valves (especially pregnant women) due to risk of valve thrombosis,Concomitant use of other drugs that significantly increase bleeding risk (e.g., warfarin, aspirin, clopidogrel) without careful monitoring and indication
No specific food interactions. Avoid grapefruit juice as it may theoretically increase nalbuphine levels (CYP3A4 substrate, though major metabolism via glucuronidation). Maintain adequate hydration to prevent constipation.
No specific food interactions. However, foods high in vitamin K (e.g., leafy greens) may theoretically affect coagulation but are not clinically significant with enoxaparin. Avoid excessive alcohol intake due to potential bleeding risk. Maintain consistent diet if also taking warfarin.
Pregnancy Category C. No adequate well-controlled studies in pregnant women. Animal studies have shown no teratogenic effects but embryocidal effects at high doses. Use only if potential benefit justifies risk. In first trimester, avoid unless necessary. Second and third trimesters: risk of neonatal respiratory depression, withdrawal if chronic use. Near term: may prolong labor and cause neonatal respiratory depression.
Enoxaparin sodium does not cross the placenta and is not associated with teratogenicity in humans. However, there is a risk of hemorrhage during delivery. Use during pregnancy requires careful monitoring for bleeding.
Excreted in breast milk in small amounts; M/P ratio approximately 0.47-1.5. Limited data; caution recommended. Monitor infant for sedation and respiratory depression. Benefits of breastfeeding should outweigh risks.
Excretion into breast milk is minimal; M/P ratio not determined. Considered compatible with breastfeeding; no known adverse effects in nursing infants, but monitor for bleeding signs.
No specific dose adjustment recommended for pregnancy, but pharmacokinetics may be altered due to increased volume of distribution and clearance. Dosing should be on an individual basis, titrated to effect. Use lowest effective dose and shortest duration. During labor, doses should be reduced due to potential for respiratory depression in neonate.
Pregnancy increases volume of distribution and clearance of enoxaparin, necessitating dose adjustment. Monitor anti-Xa levels and adjust dose to maintain target levels, typically requiring higher doses per weight in late pregnancy.
Nalbuphine is a mixed agonist-antagonist opioid with ceiling effect on respiratory depression; less abuse liability than morphine. Useful for opioid-induced pruritus (e.g., with morphine) at low doses (0.1 mg/kg IV). May precipitate withdrawal in opioid-dependent patients. Avoid in opioid-tolerant patients on full agonists. Metabolized by liver; adjust dose in hepatic impairment. Not a controlled substance (US), but report to regulatory authorities as required.
Enoxaparin is a low molecular weight heparin (LMWH) that preferentially inhibits factor Xa over thrombin. Monitor anti-Xa levels in patients with renal impairment (Cr Cl <30 m L/min), obesity, or pregnancy. Avoid intramuscular injections and use with caution in patients receiving neuraxial anesthesia due to risk of spinal hematoma. Protamine sulfate partially reverses enoxaparin (up to 60% of anti-Xa activity). Does not routinely require monitoring of a PTT.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,May cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how nalbuphine affects you.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of severe drowsiness, respiratory depression, coma, or death.,Do not stop suddenly after prolonged use; withdrawal symptoms may occur but are generally milder than with full agonists.,Report any signs of allergic reaction (rash, hives, swelling) or difficulty breathing immediately.,If you have been taking other opioids, inform your doctor to avoid withdrawal symptoms.,Store at room temperature away from heat, light, and moisture; keep out of reach of children.
Inject subcutaneously as directed, rotating injection sites (e.g., left/right abdomen, alternating).,Do not massage the injection site after administration.,Report any signs of bleeding: unusual bruising, prolonged bleeding from cuts, blood in urine or stool, coughing up blood.,Seek immediate medical attention for symptoms of spinal hematoma after neuraxial procedure: back pain, numbness or weakness in legs, bowel/bladder dysfunction.,Inform all healthcare providers (including dentists) that you are taking enoxaparin.,Avoid NSAIDs, aspirin, or other blood thinners unless prescribed by your doctor.
"The combination of trifluoperazine, a phenothiazine antipsychotic, with nalbuphine, a mixed opioid agonist-antagonist, can lead to additive central nervous system (CNS) depression, including increased sedation, respiratory depression, and hypotension. Trifluoperazine may enhance the depressant effects of nalbuphine on the brainstem respiratory centers and vasomotor centers. Clinically, this interaction may result in excessive sedation, respiratory compromise, and orthostatic hypotension, particularly in elderly or debilitated patients."
"Combined use of nalbuphine, a mixed opioid agonist-antagonist, with entacapone, a catechol-O-methyltransferase (COMT) inhibitor, may increase the risk of opioid-related adverse effects, including respiratory depression and sedation, due to additive central nervous system depression. Entacapone can also inhibit the metabolism of catecholamines, potentially exacerbating opioid-induced constipation and urinary retention. Clinically, patients may experience enhanced sedation or respiratory compromise, particularly in elderly or debilitated populations."
"Concomitant use of clozapine and nalbuphine may potentiate central nervous system (CNS) depression, leading to additive sedative and respiratory depressant effects. Both drugs act on the CNS via distinct mechanisms but converge on common pathways, increasing the risk of hypotension, bradycardia, and profound sedation. Clinically, patients may experience excessive drowsiness, confusion, or respiratory compromise, particularly in those with pre-existing comorbidities or concurrent use of other CNS depressants."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NALBUPHINE HYDROCHLORIDE vs ENOXAPARIN SODIUM, answered by our medical review team.
NALBUPHINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Mixed agonist-antagonist at mu-opioid receptor; full agonist at kappa-opioid receptor; weak antagonist at mu-opioid receptor.. ENOXAPARIN SODIUM is a Low Molecular Weight Heparin that works by Enoxaparin binds to antithrombin III (ATIII) via its pentasaccharide sequence, enhancing ATIII-mediated inhibition of factor Xa and, to a lesser extent, factor IIa (thrombin). It preferentially inhibits factor Xa over thrombin (anti-Xa:anti-IIa ratio ~3.6:1).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NALBUPHINE HYDROCHLORIDE and ENOXAPARIN SODIUM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NALBUPHINE HYDROCHLORIDE is: 10-20 mg IM/IV/SC every 3-6 hours as needed; maximum single dose 20 mg, maximum daily dose 160 mg.. The standard adult dose of ENOXAPARIN SODIUM is: 1 mg/kg subcutaneous every 12 hours or 1.5 mg/kg subcutaneous once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NALBUPHINE HYDROCHLORIDE and ENOXAPARIN SODIUM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NALBUPHINE HYDROCHLORIDE is classified as Category A/B. Pregnancy Category C. No adequate well-controlled studies in pregnant women. Animal studies have shown no teratogenic effects but embryocidal effects at high doses. Use only if pot. ENOXAPARIN SODIUM is classified as Category A/B. Enoxaparin sodium does not cross the placenta and is not associated with teratogenicity in humans. However, there is a risk of hemorrhage during delivery. Use during pregnancy requ. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.